INT17324

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 26
Total Number 26
Disease Relevance 13.50
Pain Relevance 4.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plg) extracellular space (Plg) extracellular region (Plg)
Anatomy Link Frequency
platelet 3
plasma 2
blood 2
eyes 1
joint 1
Plg (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 4 99.46 Very High Very High Very High
Inflammation 151 99.20 Very High Very High Very High
cINOD 11 99.12 Very High Very High Very High
abdominal pain 2 99.12 Very High Very High Very High
Potency 8 98.28 Very High Very High Very High
imagery 12 97.68 Very High Very High Very High
aspirin 13 96.80 Very High Very High Very High
Antinociceptive 7 95.96 Very High Very High Very High
headache 1 94.48 High High
Opioid 16 94.44 High High
Disease Link Frequency Relevance Heat
Impulse Control Disorders 164 100.00 Very High Very High Very High
Coagulation Disorder 10 99.74 Very High Very High Very High
Aggression 4 99.44 Very High Very High Very High
INFLAMMATION 156 99.20 Very High Very High Very High
Abdominal Pain 2 99.12 Very High Very High Very High
Pathologic Neovascularization 4 98.92 Very High Very High Very High
Thrombosis Related Under Development 4 98.84 Very High Very High Very High
Cancer 362 98.04 Very High Very High Very High
Diabetes Mellitus 77 97.20 Very High Very High Very High
Reprotox - General 1 13 96.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
2-plasmin inhibitor (?
Negative_regulation (inhibitor) of plasmin
1) Confidence 0.38 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.19 Pain Relevance 0.04
Prolyl-leucyl-glycinamide (PLG): inhibition of offensive aggression in mice.
Negative_regulation (inhibition) of PLG associated with aggression and narcan
2) Confidence 0.37 Published 1986 Journal Life Sci. Section Title Doc Link 2877382 Disease Relevance 0.37 Pain Relevance 0.43
Administration of streptodekase-2 brought about an increase of the total blood fibrinolytic activity (the fibrinolysis time dropped from 248.8 +/- 82.1 to 137.5 +/- 42.5 min after 12 h), plasmin activation (from 0.00 +/- 0.00 to 23.5 +/- 7.5 mg after 24 h), reduction of the plasminogen content (from 94.0 +/- 2.5 to 46.8 +/- 5.3% after 12 h).
Negative_regulation (reduction) of plasminogen in blood
3) Confidence 0.36 Published 1990 Journal Ter. Arkh. Section Abstract Doc Link 2274864 Disease Relevance 0.73 Pain Relevance 0.37
These compounds lacked PG synthetase inhibitory activity, but their inhibitory potency in MVD preparations correlated roughly with their antinociceptive potency in vivo.
Negative_regulation (lacked) of PG synthetase in MVD associated with antinociceptive and potency
4) Confidence 0.32 Published 1991 Journal J. Med. Chem. Section Abstract Doc Link 1900533 Disease Relevance 0 Pain Relevance 0.69
A reactive synovial cell proliferation, the accumulation of hybridoma and inflammatory cells in the enlarged joint space, the loss of PG from the superficial layer of the articular cartilage, and the erosion of articular surface were identical histopathologic signs to those found either in primary or adoptive transfer of PG-induced arthritis.
Negative_regulation (loss) of PG in joint associated with inflammation and arthritis
5) Confidence 0.25 Published 1995 Journal J. Immunol. Section Abstract Doc Link 7544381 Disease Relevance 0.68 Pain Relevance 0.25
The more widely studied antiangiogenic agents include naturally occurring angiogenesis inhibitors (angiostatin, endostatin, thrombospondins, platelet factor-4, etc.); inhibitors of EC growth (TNP-470, thalidomide, interleukin-12 [IL-12] etc), inhibitors of proangiogenic molecules (antibodies, antisense and soluble receptors for FGF, VEGF); agents that interfere with basement membranes and extracellular matrix (tissue inhibitors of matrix metalloproteinases [TIMPs]); antibodies to adhesion molecules (?
Negative_regulation (inhibitors) of angiostatin in platelet associated with metalloproteinase and adhesions
6) Confidence 0.19 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 1.46 Pain Relevance 0.07
Ten days after diabetes induction, retinal occludin content in eyes that received rAAV-lacZ was 11.35±3.57 pixels and 34.73±3.17 pixels in eyes that received rAAV-angiostatin occludin, a statistically significant reduction (n=5, p=0.041, Figure 5).
Negative_regulation (reduction) of angiostatin in eyes associated with diabetes mellitus
7) Confidence 0.17 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2533034 Disease Relevance 0.56 Pain Relevance 0
PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration.
Negative_regulation (inhibitor) of plasminogen in endothelial cell associated with pathologic neovascularization
8) Confidence 0.13 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2836381 Disease Relevance 0.17 Pain Relevance 0
On the other hand, oxaprozin inhibited dose-dependently PG synthetase activity.
Negative_regulation (inhibited) of PG
9) Confidence 0.12 Published 1984 Journal Nippon Yakurigaku Zasshi Section Abstract Doc Link 6432657 Disease Relevance 0.07 Pain Relevance 0.27
These results suggest that oxaprozin, like many other acidic non-steroidal anti-inflammatory drugs, suppresses platelet aggregation by mainly inhibiting PG synthetase activity.
Negative_regulation (inhibiting) of PG in platelet associated with inflammation and cinod
10) Confidence 0.12 Published 1984 Journal Nippon Yakurigaku Zasshi Section Abstract Doc Link 6432657 Disease Relevance 0.17 Pain Relevance 0.25
Plasminogen activator activity is inhibited by plasminogen activator inhibitor-1 (PAI-1) [9].
Negative_regulation (inhibited) of Plasminogen
11) Confidence 0.12 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.54 Pain Relevance 0
In these patients the following substances in plasma were determined: Prekallikrein, alpha 2-plasmin inhibitor, alpha 1-antitrypsin, alpha 2-macroglobulin, C1-inactivator, antithrombin-III, plasminogen, fibrinogen, fibrin degradation products (FDP).
Negative_regulation (inhibitor) of plasminogen in plasma
12) Confidence 0.04 Published 1985 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 2411832 Disease Relevance 0.52 Pain Relevance 0.06
Many indications suggest that the u-PA/u-PAR system, together with specific inhibitors of plasminogen activators (PAIs), is an organizer of cell-ECM contacts and covers the full range of activities required to promote and disrupt cell attachment sites [115].
Negative_regulation (inhibitors) of plasminogen
13) Confidence 0.04 Published 2004 Journal Reprod Biol Endocrinol Section Body Doc Link PMC320496 Disease Relevance 0.21 Pain Relevance 0.04
1-antichymotrypsin, plasminogen activator inhibitors, ?
Negative_regulation (inhibitors) of plasminogen
14) Confidence 0.04 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2629972 Disease Relevance 0.17 Pain Relevance 0.21
Also, a significant reduction in plasminogen and elevated C1-inactivator was observed in patients with poor prognosis.
Negative_regulation (reduction) of plasminogen
15) Confidence 0.04 Published 1985 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 2411832 Disease Relevance 0.40 Pain Relevance 0.10
Plasminogen activator inhibitors in the blood, that is, notably plasminogen activator inhibitor type 1 (PAI-1), bind circulating tissue-type plasminogen activator (t-PA).
Negative_regulation (inhibitors) of Plasminogen in blood
16) Confidence 0.03 Published 1993 Journal Dan Med Bull Section Abstract Doc Link 8222763 Disease Relevance 0.07 Pain Relevance 0
Within 2 weeks, samples were thawed and prepared for the following assays: thrombin-antithrombin complexes (TAT complexes), D-dimers, plasminogen activator inhibitor type 1 (PAI-1), and plasminogen and plasmin inhibitor.
Negative_regulation (inhibitor) of plasminogen
17) Confidence 0.03 Published 2003 Journal J Clin Anesth Section Body Doc Link 14652120 Disease Relevance 0 Pain Relevance 0
In addition, the treatment significantly reduced alveolar fibrin deposition, and decreased tissue factor and plasminogen activator inhibitor-1 activity in the serum.
Negative_regulation (decreased) of plasminogen
18) Confidence 0.02 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2211395 Disease Relevance 1.16 Pain Relevance 0.17
The binding of plasminogen to fibrin is regulated by histidine-rich glycoprotein, and the primary physiological inhibitor of generated plasmin is alpha 2-antiplasmin and especially the plasminogen-binding form of this immediate plasmin inhibitor.
Negative_regulation (inhibitor) of plasminogen
19) Confidence 0.02 Published 1993 Journal Dan Med Bull Section Abstract Doc Link 8222763 Disease Relevance 0.07 Pain Relevance 0
Among endogenous angiogenesis inhibitors, angiostatin and endostatin block ?
Negative_regulation (block) of angiostatin
20) Confidence 0.02 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592799 Disease Relevance 1.08 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox